Lanzhou Foci Pharmaceutical Co Ltd (002644) - Total Assets
Based on the latest financial reports, Lanzhou Foci Pharmaceutical Co Ltd (002644) holds total assets worth CN¥2.52 Billion CNY (≈ $369.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lanzhou Foci Pharmaceutical Co Ltd - Total Assets Trend (2007–2024)
This chart illustrates how Lanzhou Foci Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Lanzhou Foci Pharmaceutical Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Lanzhou Foci Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Lanzhou Foci Pharmaceutical Co Ltd's total assets of CN¥2.52 Billion consist of 49.5% current assets and 50.5% non-current assets. Review Lanzhou Foci Pharmaceutical Co Ltd (002644) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.1% |
| Accounts Receivable | CN¥445.78 Million | 18.1% |
| Inventory | CN¥339.99 Million | 13.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥76.87 Million | 3.1% |
| Goodwill | CN¥9.01 Million | 0.4% |
Asset Composition Trend (2007–2024)
This chart illustrates how Lanzhou Foci Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Lanzhou Foci Pharmaceutical Co Ltd share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lanzhou Foci Pharmaceutical Co Ltd's current assets represent 49.5% of total assets in 2024, an increase from 31.8% in 2007.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2024, up from 1.8% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 28.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 18.1% of total assets.
Lanzhou Foci Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Lanzhou Foci Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Lanzhou Foci Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.10 | 3.00 | 2.50 |
| Quick Ratio | 2.32 | 2.01 | 1.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥896.65 Million | CN¥817.37 Million | CN¥631.71 Million |
Lanzhou Foci Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Lanzhou Foci Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -2.3% |
| Total Assets | CN¥2.47 Billion |
| Market Capitalization | $612.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lanzhou Foci Pharmaceutical Co Ltd's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Lanzhou Foci Pharmaceutical Co Ltd's assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual total assets of Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.47 Billion ≈ $361.41 Million |
-2.31% |
| 2023-12-31 | CN¥2.53 Billion ≈ $369.94 Million |
-2.26% |
| 2022-12-31 | CN¥2.59 Billion ≈ $378.50 Million |
+9.97% |
| 2021-12-31 | CN¥2.35 Billion ≈ $344.19 Million |
-1.47% |
| 2020-12-31 | CN¥2.39 Billion ≈ $349.32 Million |
-0.56% |
| 2019-12-31 | CN¥2.40 Billion ≈ $351.30 Million |
-4.89% |
| 2018-12-31 | CN¥2.52 Billion ≈ $369.34 Million |
+7.41% |
| 2017-12-31 | CN¥2.35 Billion ≈ $343.85 Million |
+15.37% |
| 2016-12-31 | CN¥2.04 Billion ≈ $298.04 Million |
+49.49% |
| 2015-12-31 | CN¥1.36 Billion ≈ $199.36 Million |
+30.17% |
| 2014-12-31 | CN¥1.05 Billion ≈ $153.15 Million |
+15.89% |
| 2013-12-31 | CN¥903.08 Million ≈ $132.15 Million |
+9.74% |
| 2012-12-31 | CN¥822.91 Million ≈ $120.42 Million |
-0.76% |
| 2011-12-31 | CN¥829.23 Million ≈ $121.34 Million |
+81.78% |
| 2010-12-31 | CN¥456.16 Million ≈ $66.75 Million |
+8.08% |
| 2009-12-31 | CN¥422.05 Million ≈ $61.76 Million |
+5.38% |
| 2008-12-31 | CN¥400.52 Million ≈ $58.61 Million |
+11.28% |
| 2007-12-31 | CN¥359.92 Million ≈ $52.67 Million |
-- |
About Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more